Myriad Genetics Inc (MYGN) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2025, Myriad Genetics reported revenue of $824.5M, down 1.6% from $837.6M the year before. Net income was -$365.9M (a -44.4% net margin), or -$3.95 per diluted share. Gross margin was 69.9% and operating margin was -47.0%. Operating activities generated $1.8M of cash. At fiscal year end, Myriad Genetics held $706.6M in total assets against $338.6M in total liabilities, including $149.6M of cash and equivalents.
Open the full interactive Myriad Genetics financials → Quarterly statements, key ratios, valuation history and price charts.
Myriad Genetics Key Stats
| Share Price | $4.08 |
|---|---|
| Market Cap | $386.8M |
| Revenue YoY Growth | -1.6% |
| 52-Week Range | $2.86 – $8.18 |
| Shares Outstanding | 94.8 million (basic, 2026 Q2) |
Myriad Genetics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $638.6M | $690.6M | $678.4M | $753.2M | $837.6M | $824.5M |
| Cost of Goods Sold | $870.3M | $881.1M | $819.0M | $1.01B | $252.2M | $247.9M |
| Gross Profit | -$231.7M | -$190.5M | -$140.6M | -$257.4M | $585.4M | $576.6M |
| Operating Income | -$231.7M | -$190.5M | -$140.6M | -$257.4M | -$123.5M | -$387.2M |
| Pre-Tax Income | -$223.3M | -$57.1M | -$140.6M | -$262.2M | -$123.5M | -$395.1M |
| Income Tax | -$23.7M | -$29.9M | -$28.6M | $1.1M | $3.8M | -$29.2M |
| Net Income | -$199.5M | -$27.2M | -$112.0M | -$263.3M | -$127.3M | -$365.9M |
| Diluted EPS | -$2.69 | -$0.35 | -$1.39 | -$3.18 | -$1.41 | -$3.95 |
Myriad Genetics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $205.7M | $209.8M | $200.4M | $190.7M |
| Net Income | -$27.4M | -$7.9M | -$34.1M | -$43.2M |
| Diluted EPS | -$0.29 | -$0.09 | -$0.36 | -$0.46 |
Myriad Genetics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $163.7M | $258.4M | $56.9M | $132.1M | $102.4M | $149.6M |
| Current Assets | $331.7M | $484.8M | $274.6M | $313.6M | $298.0M | $332.6M |
| Total Assets | $1.40B | $1.32B | $1.20B | $1.15B | $1.03B | $706.6M |
| Current Liabilities | $147.0M | $204.3M | $137.2M | $155.9M | $164.1M | $133.8M |
| Total Long-Term Debt | $224.4M | — | — | $38.5M | $39.6M | $119.9M |
| Total Liabilities | $486.4M | $352.9M | $312.9M | $363.3M | $326.5M | $338.6M |
| Shareholders' Equity | $918.2M | $967.8M | $885.8M | $783.2M | $701.1M | $368.0M |
Myriad Genetics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $60.7M | $18.2M | -$106.3M | -$110.9M | -$8.7M | $1.8M |
| Cash From Investing | $19.3M | $274.4M | -$77.5M | $31.9M | -$11.9M | -$27.4M |
| Cash From Financing | -$10.0M | -$150.6M | -$8.0M | $152.9M | -$7.4M | $64.2M |
| Free Cash Flow | $50.5M | $200,000 | -$151.6M | — | — | — |
Figures from Myriad Genetics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Myriad Genetics financials page for every line item.
Myriad Genetics Company Profile
| Ticker | MYGN |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Salt Lake City, Utah |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0000899923 |
Frequently Asked Questions
What was Myriad Genetics' revenue in fiscal 2025?
Myriad Genetics (MYGN) reported revenue of $824.5M for fiscal 2025.
What is Myriad Genetics' annual revenue history?
Myriad Genetics' annual revenue by fiscal year: 2020: $638.6M; 2021: $690.6M; 2022: $678.4M; 2023: $753.2M; 2024: $837.6M; 2025: $824.5M.
What was Myriad Genetics' net income in fiscal 2025?
Myriad Genetics reported net income of -$365.9M for fiscal 2025.
What was Myriad Genetics' earnings per share (EPS) in fiscal 2025?
Myriad Genetics' diluted EPS was -$3.95 for fiscal 2025 (adjusted for any later stock splits).
What was Myriad Genetics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Myriad Genetics reported revenue of $190.7M.
How much debt does Myriad Genetics have?
Myriad Genetics reported $119.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Myriad Genetics are outstanding?
Myriad Genetics reported a weighted average of 94.8 million basic shares outstanding in 2026 Q2.
What is Myriad Genetics' market cap?
Based on its latest closing price, Myriad Genetics (MYGN) has a market capitalization of about $386.8M.
When does Myriad Genetics' fiscal year end?
Myriad Genetics' fiscal year end, as registered with the SEC, is December 31.
Where is Myriad Genetics headquartered?
Myriad Genetics lists its business address in Salt Lake City, Utah in its SEC filings.
Myriad Genetics Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →